A Phase 4 interventional study of BENZOYL PEROXIDE/ CLINDAMYCIN and BENZOYL PEROXIDE/ ADAPALENE in Acne Vulgaris, sponsored by Stiefel, a GSK Company. Completed at 4 sites in Argentina. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2016-12-13.
Sponsored by Stiefel, a GSK Company (part of GlaxoSmithKline) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies testing Benzoyl Peroxide in Acne Vulgaris — none open to participants now, 1 under way, none of them phase 3. Benzoyl Peroxide · Acne Vulgaris.
Among the 33 studies testing Benzoyl Peroxide in Acne Vulgaris, this one is the 24th largest by enrollment, is one of 6 that started in 2009, is one of 16 in phase 4, and was the 12th registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →None of the 33 studies testing Benzoyl Peroxide in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →
Benzoyl Peroxide: first FDA approval 1984 (BENZAMYCIN). What it is approved for, and how studies give it, is on its page →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 6 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 90 across the 33 interventional studies. Of the 28 that completed or were terminated, 24 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 33 have an industry lead sponsor. The 10 most frequent:
This study is registered under Stiefel, a GSK Company, one of the names counted as GlaxoSmithKline. Under that name alone:
Stiefel, a GSK Company is the lead sponsor of 56 studies on the registry; none are open to participants now.
42 studies in Acne Vulgaris by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 42 finished, 24 (57%) have results posted.
Among the 42 studies in Acne Vulgaris by GlaxoSmithKline, this one is the 25th largest by enrollment, is one of 13 that started in 2009, is one of 16 in phase 4, and was the 10th registered.
GlaxoSmithKline’s Acne Vulgaris studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 33 studies testing Benzoyl Peroxide in Acne Vulgaris, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 42 in Acne Vulgaris:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the tolerability of topical combination therapies in the treatment of facial acne.
The purpose of this study is to compare the tolerability of topical combination therapies in the treatment of facial acne.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subject will apply both study products in a split-face fashion. Study products will be applied once-daily in the evening.
Drug: BENZOYL PEROXIDE/ CLINDAMYCIN
Subject will apply both study products in a split-face fashion. Study products will be applied once-daily in the evening.
Drug: BENZOYL PEROXIDE/ ADAPALENE
Drug pages: Benzoyl Peroxide · Clindamycin
Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply benzoyl peroxide/clindamycin gel to the entire face for an additional 6 weeks.
Drug pages: Benzoyl Peroxide · Adapalene
Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply benzoyl peroxide/clindamycin gel to the entire face for an additional 6 weeks.
Erythema (Redness)
Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
Time frame: Weeks 1 and 2
Skin Dryness
Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
Time frame: Weeks 1 and 2
Skin Peeling
Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3,Intense.
Time frame: Weeks 1 and 2
Irritant/Allergic Contact Dermatitis
Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
Time frame: Weeks 1 and 2
Erythema (Redness)
Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
Time frame: Weeks 5 and 8
Skin Dryness
Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
Time frame: Weeks 5 and 8
Skin Peeling
Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
Time frame: Weeks 5 and 8
Irritant/Allergic Contact Dermatitis
Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
Time frame: Weeks 5 and 8
Investigators Static Global Assessment
ISGA is evaluated using the following scale: 0, Clear: Clear skin with no lesions; 1, Almost Clear: Rare non-inflammatory lesions; 2, Mild: Some non-inflammatory lesions with no more than a few inflammatory lesions but no nodular lesions); 3, Moderate: Up to many non-inflammatory lesions and may have some inflammatory lesions, but no more than 1 small nodular lesion; 4, Severe: Up to many non-inflammatory and inflammatory lesions, but no more than a few nodular lesions; 5, Very Severe: Many non-inflammatory and inflammatory lesions and more than a few nodular lesions. May have cystic lesions.
Time frame: Baseline, Weeks 5, 8
Total Acne Lesion Counts
Total acne lesion counts - includes both inflammatory acne lesions (pustules, papules), noninflammatory lesions (whiteheads and blackheads),
Time frame: Baseline, Weeks 5 and 8
Inflammatory Acne Lesion Counts
Total number of inflammatory acne lesions (pustules, papules) at each timepoint.
Time frame: Baseline, Weeks 5 and 8
Non-inflammatory Acne Lesion Counts
Total number of non-inflammatory acne lesions (whiteheads and blackheads) at each timepoint.
Time frame: Baseline, Weeks 5 and 8
Skindex-29 Quality of Life Questionnaire (QoL) - Symptomatic Domain
Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. The symptomatic score (score=0 to 28)=(sum of the 7 individual item scores) \* 100/28.
Time frame: Baseline, Weeks 2 and 8
Quality of Life Questionnaire - Emotional Domain
Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. The emotional score (score=0 to 40)=(sum of the 10 individual item scores) \* 100/40.
Time frame: Baseline, Weeks 2 and 8
Quality of Life Questionnaire - Functional Domain
Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. The functional score (score=0 to 48)=(sum of the 12 individual item scores) \* 100/48.
Time frame: Baseline, Weeks 2 and 8
Quality of Life Questionnaire - Global Score
Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. A Global Score (range 0-100)=(sum of all 29 individual item scores) \* 100/116.
Time frame: Baseline, Weeks 2 and 8
Product Acceptability and Preference Questionnaire - Severity of Redness at Weeks 1 and 2
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.
Time frame: Weeks 1 and 2
Product Acceptability and Preference Questionnaire - Severity of Redness at Week 8
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.
Time frame: Week 8
Product Acceptability and Preference Questionnaire - Severity of Dryness at Weeks 1 and 2
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.
Time frame: Weeks 1 and 2
Product Acceptability and Preference Questionnaire - Severity of Dryness at Week 8
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.
Time frame: Week 8
Product Acceptability and Preference Questionnaire - Severity of Burning at Weeks 1 and 2
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.
Time frame: Weeks 1 and 2
Product Acceptability and Preference Questionnaire - Severity of Burning at Week 8
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.
Time frame: Week 8
Product Acceptability and Preference Questionnaire - Severity of Itching at Weeks 1 and 2
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.
Time frame: Weeks 1 and 2
Product Acceptability and Preference Questionnaire - Severity of Itching at Week 8
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.
Time frame: Week 8
Product Acceptability and Preference Questionnaire - Severity of Scaling at Weeks 1 and 2
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe; 5, Very Severe.
Time frame: Weeks 1 and 2
Product Acceptability and Preference Questionnaire - Severity of Scaling at Week 8
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe; 5, Very Severe.
Time frame: Week 8
Product Acceptability and Preference Questionnaire - Ease of Application of Product at Weeks 1 and 2
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very easy; 2, Easy; 3, Neutral; 4, Difficult.
Time frame: Weeks 1 and 2
Product Acceptability and Preference Questionnaire - Ease of Application of Product at Week 8
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, Very easy; 2, Easy; 3, Neutral; 4, Difficult.
Time frame: Week 8
Product Acceptability and Preference Questionnaire - Comfort of Skin at Weeks 1 and 2
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Comfortable; 2, Comfortable; 3, Somewhat Comfortable; 4, Somewhat Uncomfortable; 5, Uncomfortable.
Time frame: Weeks 1 and 2
Product Acceptability and Preference Questionnaire - Comfort of Skin at Week 8
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Comfortable; 2, Comfortable; 3, Somewhat Comfortable; 4, Somewhat Uncomfortable; 5, Uncomfortable.
Time frame: Week 8
Product Acceptability and Preference Questionnaire - Which Study Product is Subject More Satisfied With? at Weeks 1 and 2
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following choices: Epiduo, Clindoxyl Gel, Both Treatments Equally.
Time frame: Weeks 1 and 2
Product Acceptability and Preference Questionnaire - Comparison of Study Products Used in the Past at Week 8
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, More Satisfied; 2, Somewhat More Satisfied; 3, Neither Satisfied or Dissatisfied; 4, Somewhat More Dissatisfied; 5, More Dissatisfied.
Time frame: Week 8
Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products at Weeks 1 and 2
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Highly Favorable; 2, Favorable; 3, Neutral; 4, Unfavorable; 5, Uncomfortable.
Time frame: Weeks 1 and 2
Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products at Week 8
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, Highly Favorable; 2, Favorable; 3, Neutral; 4, Unfavorable; 5, More Dissatisfied.
Time frame: Week 8
Product Acceptability and Preference Questionnaire - Compliance at Weeks 1 and 2
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, Not Compliant at all; 1, Mostly Compliant; 2, Very Compliant.
Time frame: Weeks 1 and 2
Product Acceptability and Preference Questionnaire - Compliance at Week 8
Product Acceptability and Preference Questionnaire were completed by the subject at week 8 by answering Yes or No to the following question: Did you use the product every day?. When only one product was applied to the face, subjects were asked to rate their compliance by answering the aforementioned question, rather than rating compliance on a 0-2 scale.
Time frame: Week 8
Product Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin at Weeks 1 and 2
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint by answering Yes or No to the following question: Did you feel that your skin was hydrated and moisturized while you were on your study product?
Time frame: Weeks 1 and 2
Product Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin at Week 8
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint by answering Yes or No to the following question: Did you feel that your skin was hydrated and moisturized while you were on your study product?
Time frame: Week 8
Product Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment at Week 1 and 2
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint by answering Yes or No to the following question: If you were to choose to continue treatment for your acne, would you use the study product?
Time frame: Weeks 1 and 2
Product Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment at Week 8
Product Acceptability and Preference Questionnaire were completed by the subject at 8 week timepoint by answering Yes or No to the following question: If you were to choose to continue treatment for your acne, would you use the study product?
Time frame: Week 8
Product Acceptability and Preference Questionnaire - Ease of Use Wtih Make-Up at Weeks 1 and 2
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, Not Applicable; 1, Very Easy; 2, Easy; 3, Neutral; 4, Difficult; 5, Very Difficult.
Time frame: Weeks 1 and 2
Product Acceptability and Preference Questionnaire - Ease of Use With Make-Up at Week 8
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, Not Applicable; 1, Very Easy; 2, Easy; 3, Neutral; 4, Difficult; 5, Very Difficult.
Time frame: Week 8
Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product at Weeks 1 and 2
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Satisfied; 2, Satisfied; 3, Neutral; 4, Unsatisfied; 5, Very Unsatisfied.
Time frame: Weeks 1 and 2
Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product at Week 8
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Satisfied; 2, Satisfied; 3, Neutral; 4, Unsatisfied; 5, Very Unsatisfied.
Time frame: Week 8
Clinical research center
| Milestone | Clindoxyl and Epiduo Gels |
|---|---|
| Started | 48 |
| Completed | 48 |
| Not completed | 0 |
| Milestone | Clindoxyl and Epiduo Gels |
|---|---|
| Started | 48 |
| Completed | 45 |
| Not completed | 3 |
| Withdrew: Adverse event | 1 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Pregnancy | 1 |
Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
| units on a scale | Clindoxyl Gel | Epiduo Gel |
|---|---|---|
| Week 1 | 0.66 ± 0.70 | 0.91 ± 0.78 |
| Week 2 | 0.55 ± 0.62 | 0.74 ± 0.64 |
Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
| units on a scale | Clindoxyl Gel |
|---|---|
| Week 5 | 0.22 ± 0.42 |
| Week 8 | 0.19 ± 0.50 |
Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
| units on a scale | Clindoxyl Gel |
|---|---|
| Week 5 | 0.20 ± 0.46 |
| Week 8 | 0.04 ± 0.29 |
Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
| units on a scale | Clindoxyl Gel | Epiduo Gel |
|---|---|---|
| Week 1 | 0.47 ± 0.55 | 0.96 ± 0.75 |
| Week 2 | 0.40 ± 0.58 | 0.64 ± 0.74 |
Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3,Intense.
| units on a scale | Clindoxyl Gel | Epiduo |
|---|---|---|
| Week 1 | 0.34 ± 0.52 | 0.68 ± 0.78 |
| Week 2 | 0.40 ± 0.61 | 0.60 ± 0.68 |
Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
| units on a scale | Clindoxyl Gel | Epiduo Gel |
|---|---|---|
| Week 1 | 0.04 ± 0.20 | 0.04 ± 0.20 |
| Week 2 | 0.04 ± 0.20 | 0.04 ± 0.20 |
Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
| units on a scale | Clindoxyl Gel |
|---|---|
| Week 5 | 0.13 ± 0.40 |
| Week 8 | 0.06 ± 0.25 |
Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
| units on a scale | Clindoxyl Gel |
|---|---|
| Week 5 | 0.00 ± 0.00 |
| Week 8 | 0.00 ± 0.00 |
ISGA is evaluated using the following scale: 0, Clear: Clear skin with no lesions; 1, Almost Clear: Rare non-inflammatory lesions; 2, Mild: Some non-inflammatory lesions with no more than a few inflammatory lesions but no nodular lesions); 3, Moderate: Up to many non-inflammatory lesions and may have some inflammatory lesions, but no more than 1 small nodular lesion; 4, Severe: Up to many non-inflammatory and inflammatory lesions, but no more than a few nodular lesions; 5, Very Severe: Many non-inflammatory and inflammatory lesions and more than a few nodular lesions. May have cystic lesions.
| units on a scale | Clindoxyl Gel |
|---|---|
| Baseline | 2.77 ± 0.56 |
| Week 5 | 1.89 ± 0.75 |
| Week 8 | 1.62 ± 0.92 |
Total acne lesion counts - includes both inflammatory acne lesions (pustules, papules), noninflammatory lesions (whiteheads and blackheads),
| Acne Lesions | Clindoxyl Gel |
|---|---|
| Baseline | 39.06 ± 12.95 |
| Week 5 | 15.96 ± 10.37 |
| Week 8 | 13.77 ± 11.50 |
Total number of inflammatory acne lesions (pustules, papules) at each timepoint.
| Acne Lesions | Clindoxyl Gel |
|---|---|
| Baseline | 14.23 ± 9.06 |
| Week 5 | 4.60 ± 3.93 |
| Week 8 | 4.26 ± 5.84 |
Total number of non-inflammatory acne lesions (whiteheads and blackheads) at each timepoint.
| Acne Lesions | Clindoxyl Gel |
|---|---|
| Baseline | 24.83 ± 12.84 |
| Week 5 | 11.36 ± 7.89 |
| Week 8 | 9.51 ± 8.53 |
Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. The symptomatic score (score=0 to 28)=(sum of the 7 individual item scores) \* 100/28.
| Units on a scale | Clindoxyl Gel |
|---|---|
| Baseline | 20.91 ± 15.73 |
| Week 2 | 21.58 ± 14.17 |
| Week 8 | 13.75 ± 14.03 |
Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. The emotional score (score=0 to 40)=(sum of the 10 individual item scores) \* 100/40.
| Units on a scale | Clindoxyl Gel |
|---|---|
| Baseline | 25.32 ± 19.73 |
| Week 2 | 19.38 ± 18.68 |
| Week 8 | 16.42 ± 19.08 |
Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. The functional score (score=0 to 48)=(sum of the 12 individual item scores) \* 100/48.
| Units on a scale | Clindoxyl Gel |
|---|---|
| Baseline | 8.59 ± 13.98 |
| Week 2 | 6.30 ± 11.77 |
| Week 8 | 5.19 ± 11.78 |
Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. A Global Score (range 0-100)=(sum of all 29 individual item scores) \* 100/116.
| Units on a scale | Clindoxyl Gel |
|---|---|
| Baseline | 8.59 ± 13.98 |
| Week 2 | 6.30 ± 11.77 |
| Week 8 | 5.19 ± 11.78 |
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.
| Units on a scale | Clindoxyl Gel | Epiduo Gel |
|---|---|---|
| Week 1 | 1.09 ± 1.18 | 1.72 ± 1.21 |
| Week 2 | 0.72 ± 0.86 | 1.15 ± 1.07 |
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.
| Units on a scale | Clindoxyl Gel |
|---|---|
| Product Acceptability and Preference Questionnaire - Severity of Redness at Week 8 | 0.77 ± 1.09 |
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.
| Units on a scale | Clindoxyl Gel | Epiduo Gel |
|---|---|---|
| Week 1 | 1.30 ± 1.14 | 1.81 ± 1.14 |
| Week 2 | 1.00 ± 0.87 | 1.41 ± 1.17 |
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.
| Units on a scale | Clindoxyl Gel |
|---|---|
| Product Acceptability and Preference Questionnaire - Severity of Dryness at Week 8 | 0.64 ± 0.97 |
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.
| Units on a scale | Clindoxyl Gel | Epiduo Gel |
|---|---|---|
| Week 1 | 0.91 ± 1.23 | 1.68 ± 1.20 |
| Week 2 | 0.72 ± 0.89 | 1.30 ± 1.23 |
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.
| Units on a scale | Clindoxyl Gel |
|---|---|
| Product Acceptability and Preference Questionnaire - Severity of Burning at Week 8 | 0.36 ± 0.76 |
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.
| Units on a scale | Clindoxyl Gel | Epiduo Gel |
|---|---|---|
| Week 1 | 0.64 ± 1.11 | 1.02 ± 1.34 |
| Week 2 | 0.72 ± 0.96 | 0.93 ± 1.00 |
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.
| Units on a scale | Clindoxyl Gel |
|---|---|
| Product Acceptability and Preference Questionnaire - Severity of Itching at Week 8 | 0.26 ± 0.49 |
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe; 5, Very Severe.
| Units on a scale | Clindoxyl Gel | Epiduo Gel |
|---|---|---|
| Week 1 | 0.79 ± 1.18 | 1.43 ± 1.41 |
| Week 2 | 0.59 ± 0.69 | 1.04 ± 1.07 |
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe; 5, Very Severe.
| Units on a scale | Clindoxyl Gel |
|---|---|
| Product Acceptability and Preference Questionnaire - Severity of Scaling at Week 8 | 0.45 ± 0.83 |
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very easy; 2, Easy; 3, Neutral; 4, Difficult.
| Units on a scale | Clindoxyl Gel | Epiduo Gel |
|---|---|---|
| Week 1 | 1.30 ± 0.51 | 1.32 ± 0.56 |
| Week 2 | 1.35 ± 0.53 | 1.39 ± 0.61 |
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, Very easy; 2, Easy; 3, Neutral; 4, Difficult.
| Units on a scale | Clindoxyl Gel |
|---|---|
| Product Acceptability and Preference Questionnaire - Ease of Application of Product at Week 8 | 1.26 ± 0.44 |
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Comfortable; 2, Comfortable; 3, Somewhat Comfortable; 4, Somewhat Uncomfortable; 5, Uncomfortable.
| Units on a scale | Clindoxyl Gel | Epiduo Gel |
|---|---|---|
| Week 1 | 2.81 ± 0.88 | 3.15 ± 1.08 |
| Week 2 | 2.39 ± 0.93 | 2.67 ± 0.94 |
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Comfortable; 2, Comfortable; 3, Somewhat Comfortable; 4, Somewhat Uncomfortable; 5, Uncomfortable.
| Units on a scale | Clindoxyl Gel |
|---|---|
| Product Acceptability and Preference Questionnaire - Comfort of Skin at Week 8 | 1.83 ± 0.92 |
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following choices: Epiduo, Clindoxyl Gel, Both Treatments Equally.
| Participants | All Subjects |
|---|---|
| Week 1, Epiduo Gel, n=47 | 15 |
| Week 1, Clindoxyl Gel, n=47 | 30 |
| Week 1, Both Treatments Equally, n=47 | 2 |
| Week 2, Epiduo Gel, n=46 | 16 |
| Week 2, Clindoxyl Gel, n=46 | 29 |
| Week 2, Both Treatments Equally, n=46 | 1 |
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, More Satisfied; 2, Somewhat More Satisfied; 3, Neither Satisfied or Dissatisfied; 4, Somewhat More Dissatisfied; 5, More Dissatisfied.
| Units on a scale | Clindoxyl Gel |
|---|---|
| Product Acceptability and Preference Questionnaire - Comparison of Study Products Used in the Past at Week 8 | 1.63 ± 1.08 |
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Highly Favorable; 2, Favorable; 3, Neutral; 4, Unfavorable; 5, Uncomfortable.
| Units on a scale | Clindoxyl Gel | Epiduo Gel |
|---|---|---|
| Week 1 | 1.87 ± 0.68 | 2.04 ± 0.78 |
| Week 2 | 1.85 ± 0.84 | 2.00 ± 0.70 |
Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, Highly Favorable; 2, Favorable; 3, Neutral; 4, Unfavorable; 5, More Dissatisfied.
| Units on a scale | Clindoxyl Gel |
|---|---|
| Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products at Week 8 | 1.53 ± 0.65 |
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, Not Compliant at all; 1, Mostly Compliant; 2, Very Compliant.
| Units on a scale | Clindoxyl Gel | Epiduo Gel |
|---|---|---|
| Week 1 | 1.91 ± 0.28 | 1.91 ± 0.28 |
| Week 2 | 1.85 ± 0.42 | 1.85 ± 0.42 |
Product Acceptability and Preference Questionnaire were completed by the subject at week 8 by answering Yes or No to the following question: Did you use the product every day?. When only one product was applied to the face, subjects were asked to rate their compliance by answering the aforementioned question, rather than rating compliance on a 0-2 scale.
| Participants | Clindoxyl Gel |
|---|---|
| Yes | 43 |
| No | 3 |
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint by answering Yes or No to the following question: Did you feel that your skin was hydrated and moisturized while you were on your study product?
| Participants | Clindoxyl Gel | Epiduo Gel |
|---|---|---|
| Week 1 - Yes | 16 | 12 |
| Week 1 - No | 31 | 35 |
| Week 2 - Yes | 14 | 11 |
| Week 2 - No | 32 | 35 |
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint by answering Yes or No to the following question: Did you feel that your skin was hydrated and moisturized while you were on your study product?
| Participants | Clindoxyl Gel |
|---|---|
| Yes | 28 |
| No | 18 |
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint by answering Yes or No to the following question: If you were to choose to continue treatment for your acne, would you use the study product?
| Participants | Clindoxyl Gel | Epiduo Gel |
|---|---|---|
| Week 1 - Yes | 44 | 26 |
| Week 1 - No | 3 | 21 |
| Week 2 - Yes | 39 | 32 |
| Week 2 - No | 7 | 14 |
Product Acceptability and Preference Questionnaire were completed by the subject at 8 week timepoint by answering Yes or No to the following question: If you were to choose to continue treatment for your acne, would you use the study product?
| Participants | Clindoxyl Gel |
|---|---|
| Yes | 41 |
| No | 5 |
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, Not Applicable; 1, Very Easy; 2, Easy; 3, Neutral; 4, Difficult; 5, Very Difficult.
| Units on a scale | Clindoxyl Gel | Epiduo Gel |
|---|---|---|
| Week 1 | 2.23 ± 1.24 | 2.31 ± 1.38 |
| Week 2 | 1.75 ± 0.93 | 1.75 ± 0.93 |
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, Not Applicable; 1, Very Easy; 2, Easy; 3, Neutral; 4, Difficult; 5, Very Difficult.
| Units on a scale | Clindoxyl Gel |
|---|---|
| Product Acceptability and Preference Questionnaire - Ease of Use With Make-Up at Week 8 | 1.69 ± 0.87 |
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Satisfied; 2, Satisfied; 3, Neutral; 4, Unsatisfied; 5, Very Unsatisfied.
| Units on a scale | Clindoxyl Gel | Epiduo Gel |
|---|---|---|
| Week 1 | 2.09 ± 0.69 | 2.23 ± 0.87 |
| Week 2 | 1.76 ± 0.77 | 1.98 ± 0.68 |
Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Satisfied; 2, Satisfied; 3, Neutral; 4, Unsatisfied; 5, Very Unsatisfied.
| Units on a scale | Clindoxyl Gel |
|---|---|
| Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product at Week 8 | 1.61 ± 0.98 |
Collected over Baseline through Week 8.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Clindoxyl and Epiduo Gels | — | 0/48 (0%) | 44/48 (91.7%) |
| Event | Clindoxyl and Epiduo Gels |
|---|---|
| Application site irritationSkin and subcutaneous tissue disorders | 36/48 |
| Application site drynessSkin and subcutaneous tissue disorders | 19/48 |
| Application site pruritusSkin and subcutaneous tissue disorders | 11/48 |
| Application site exfoliationSkin and subcutaneous tissue disorders | 10/48 |
| Drug intoleranceSkin and subcutaneous tissue disorders | 4/48 |
| Age, Continuous(years) | Clindoxyl and Epiduo Gels |
|---|---|
| Mean | 27.6 ± 5.5 |
| Gender(Participants) | Clindoxyl and Epiduo Gels |
|---|---|
| Female | 10 |
| Male | 38 |
| Ethnicity (NIH/OMB)(Participants) | Clindoxyl and Epiduo Gels |
|---|---|
| Hispanic or Latino | 33 |
| Not Hispanic or Latino | 15 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Clindoxyl and Epiduo Gels |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 48 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Clindoxyl and Epiduo Gels |
|---|---|
| Argentina | 48 |
| Investigators Static Global Assessment (ISGA)(Participants) | Clindoxyl and Epiduo Gels |
|---|---|
| Mild | 14 |
| Moderate | 31 |
| Severe | 3 |
| Inflammatory Acne Lesion Count(Inflammatory lesions) | Clindoxyl and Epiduo Gels |
|---|---|
| Mean | 14.2 ± 9.1 |
| Non-Inflammatory Acne Lesion Count(Non-Infammatory acne lesions) | Clindoxyl and Epiduo Gels |
|---|---|
| Mean | 24.8 ± 12.8 |
1 further baseline measures are reported on the registry.
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Feb 2009, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2012, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Benzoyl Peroxide · Clindamycin